Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Buqitongluo Granule** is an orally administered multi-herb traditional Chinese medicine formulation developed and manufactured by Shaanxi Buchang Pharmaceuticals for treatment of the traditional Chinese medicine pattern of qi deficiency and blood stasis. It was evaluated in the randomized, double-blind, placebo-controlled BOSS basket trial in patients with this syndrome associated with ischemic stroke, stable angina pectoris, or diabetic peripheral neuropathy. The product is intended in traditional Chinese medicine to tonify qi and promote blood circulation; its specific molecular targets and clinically established pharmacologic mechanism have not been defined. ([europepmc.org](https://europepmc.org/article/PMC/PMC8558407))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Buqitongluo Granule.